News Update

Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference

News Update
  ()
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. read more >

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

Research Report
  ()
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. read more >

5 Small-Caps on Fund Manager Steve Palmer's Radar Screen

  ()
Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention. read more >

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

Research Report
  ()
A Ladenburg Thalmann report reviewed the study design and purpose. read more >

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

Research Report
  ()
This California company expects results from clinical trials in liver disease and psoriasis in 2019. read more >

Large US Market Now Open to Livestock Feed Antibiotic Replacement

  ()
Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. read more >

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products

Research Report
  ()
A ROTH Capital Partners report presented the reasons for investing in this company. read more >

Coverage Initiated on Cancer Vaccine Firm

Research Report
  ()
An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. read more >
News Update

Augmented Reality and Healthcare Tech Firms to Collaborate

News Update
  ()
The companies aim to combine their expertise to co-create immersive and compelling instructive medical tools. read more >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Research Report
  ()
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. read more >

Expert Investing Ideas

"DRRX's current valuation is an interesting buying opportunity."

–Francois Brisebois, Laidlaw & Company


"DRRX's Posimir comes back in play."

–Ed Arce, H.C. Wainwright & Co.


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


"I'm excited about the new team Sproutly is bringing on."

–Jimmy Mengel, Marijuana Minifesto


"VIV signed a partnership with CSA Animal Nutrition."

–Alex Koyfman, Penny Stock Millionaire


"We are initiating coverage on PMN with an Outperform rating."

–Cosme Ordonez, Noble Capital Markets


"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

After Financing Close, Biotech's Subsidiary to Operate Independently

Research Report
  ()
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. read more >
News Update

Firm Launches App to Help Physicians Provide Virtual Counseling

News Update
  ()
This new initiative combines emerging technologies and human skill-based expertise. read more >

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

Research Report
  ()
This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. read more >

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

Research Report
  ()
The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. read more >